---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-110564"
form_type: "8-K"
ticker: "NEOG"
cik: "0000711377"
company_name: "NEOGEN CORP"
filed_at: "2024-10-01T23:59:59+00:00"
generated_at: "2026-05-31T00:04:10.753690+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Neogen appoints QIAGEN CEO Thierry Bernard to board of directors

## Summary
- Thierry Bernard appointed to Neogen Board of Directors, effective November 1, 2024.
- Bernard is CEO of QIAGEN N.V. (NYSE: QGEN), a global molecular insights provider.
- Bernard previously held senior roles at bioMérieux SA over 15 years.
- Board determined Bernard qualifies as independent under Nasdaq listing standards.
- Board Chair Jim Borel highlighted Bernard's science and technology expertise.

## SEC filing metadata
- accession: 0000950170-24-110564
- form_type: 8-K
- ticker: NEOG
- cik: 0000711377
- company_name: NEOGEN CORP
- filed_at: 2024-10-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/711377/000095017024110564/0000950170-24-110564-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/711377/000095017024110564/neog-20240925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-110564
- JSON: https://secwatch.observer/filing/0000950170-24-110564.json
- Plain text: https://secwatch.observer/filing/0000950170-24-110564.txt

## Key facts
- Executive change
  Thierry Bernard was appointed as Director at NEOGEN CORP.
  - Action: appointed
  - Role: Director
  source text: Neogen Corporation announced today that it has appointed Thierry Bernard to its Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/711377/000095017024110564/0000950170-24-110564-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.